InsiderTrades

Form 4 for NBIX NEUROCRINE BIOSCIENCES INC

Accepted 2024-02-15 00:00:00 ET · period of report 2024-02-13 · accession 0000914475-24-000074 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-02-15 2024-02-13 NBIX Lippoldt Darin CLO S - Sale $132.99 -1,098 39.7K -3% -$146.0K
DM 2024-02-15 2024-02-13 NBIX Lippoldt Darin CLO A - Grant $0.00 +48.6K 8,070 New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-02-13 S D 1,098 $132.99 39,740 D — — (F2) Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $134.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
2 Derivative Stock Option 2024-02-13 A A 40,552 $0.00 40,552 D $133.84 · — to 2034-02-13 40,552 Common Stock (F3) Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
3 Derivative Restricted Stock Unit 2024-02-13 A A 8,070 $0.00 8,070 D — · — to — 8,070 Common Stock (F4) Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. (F5) The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028.